What It Is
Tirzepatide is a synthetic peptide medication that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.[4][5] Incretins help coordinate insulin release, appetite, and glucose handling after meals, and the approved tirzepatide products are formulated for once-weekly subcutaneous dosing.
In the United States, Mounjaro is FDA-approved for improving glycemic control in adults with type 2 diabetes; Zepbound is approved for chronic weight management in specified adults and for moderate-to-severe obstructive sleep apnea in adults with obesity.[1][2][3] These approvals apply to the named products, presentations, indications, and labels — not to an unverified powder sold as a "research vial."
How It Works
By activating GLP-1 and GIP receptors, tirzepatide influences glucose-dependent insulin secretion, glucagon, gastric emptying, appetite, and food intake.[5][9] The exact contribution of each receptor to clinical outcomes remains an active research question.
Hypoglycemia risk rises when tirzepatide is combined with insulin or insulin secretagogues. Delayed gastric emptying can also affect absorption of oral medicines, including oral contraceptives; product-specific instructions are in the current FDA labels.[1][2]
What the Research Shows
The SURPASS program evaluated tirzepatide in type 2 diabetes. In SURPASS-2, tirzepatide produced larger mean A1C and weight reductions than semaglutide 1 mg over 40 weeks, with gastrointestinal effects common in both groups.[6] That trial does not compare every semaglutide product or dose.
SURMOUNT-1 reported substantial dose-related weight reductions over 72 weeks in adults with obesity or overweight without diabetes, and SURMOUNT-2 studied adults who also had type 2 diabetes.[7][15] Separate randomized evidence supports the obstructive-sleep-apnea indication, while SURMOUNT-4 found weight regain after randomized withdrawal.[16][17] Claims about anti-aging or performance enhancement are not supported by this trial base.
Safety & Side Effects
The most common adverse effects across trials and labeling are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal discomfort, often more pronounced during escalation.[1][2] Current labels also describe serious risks and precautions.
- Boxed warning for thyroid C-cell tumors seen in rodents, with unknown relevance to humans; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2
- Severe gastrointestinal reactions, pancreatitis, gallbladder disease, and acute kidney injury due to volume depletion
- Hypoglycemia risk when combined with insulin or insulin secretagogues
- Serious hypersensitivity reactions
- Potential effects on oral-medication absorption, including specific contraceptive guidance after initiation and escalation
Regulatory Status
Tirzepatide approval is product- and indication-specific: Mounjaro for type 2 diabetes, and Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity.[1][2][3] Those approvals cover exact formulations, manufacturing controls, labeling, and studied uses.
Compounded or research-labeled tirzepatide is a separate, unapproved category. FDA warns that unapproved GLP-1 products have not undergone premarket review and in 2026 proposed excluding tirzepatide and semaglutide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them from bulk substances; that proposal is a regulatory process, not a statement that all lawful patient-specific compounding is categorically impossible.[8][18] An unverified 10 mg powder vial should not be treated as equivalent to an FDA-approved 10 mg presentation.
How Tirzepatide Differs From Semaglutide
Tirzepatide is often compared with semaglutide, a GLP-1 receptor agonist. In SURPASS-2, tirzepatide produced greater mean A1C and body-weight reductions than semaglutide 1 mg in people with type 2 diabetes, but that comparison does not cover every semaglutide dose, product, or population.[6]
The dual-receptor mechanism is pharmacologically different; it does not establish that tirzepatide is the right option for every person. Tolerability, contraindications, access, and medical history require clinician assessment rather than inference from trial averages.